Company news
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) news
Olema Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 2, 2026: Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
August 13, 2026
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
August 10, 2026
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
May 26, 2026
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
May 21, 2026
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
May 12, 2026
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
April 29, 2026
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
April 21, 2026
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
April 17, 2026
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
March 16, 2026
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
March 15, 2026
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
February 19, 2026
Olema Oncology to Participate in Upcoming Investor Conferences
February 4, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 3, 2026
Olema Oncology Announces Departure of Chief Operating and Financial Officer
January 30, 2026
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
November 20, 2025
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 19, 2025
Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock
November 18, 2025
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
November 17, 2025
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
November 9, 2025
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
October 29, 2025
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
October 17, 2025
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
September 1, 2025
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
August 10, 2025
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
May 27, 2025
Olema Oncology Reports First Quarter 2025 Financial and Operating Results
May 12, 2025
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
April 24, 2025
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
March 24, 2025
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
March 17, 2025
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
February 18, 2025
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
February 17, 2025
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 1, 2025
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
December 9, 2024
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
December 8, 2024
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
December 1, 2024
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
November 24, 2024
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
November 23, 2024
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 11, 2024
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
October 22, 2024
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 8, 2024
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
August 20, 2024
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 5, 2024
Olema Oncology to Participate in Upcoming Investor Conferences in June
May 27, 2024
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
May 14, 2024
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 7, 2024
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
May 7, 2024
Olema Oncology to Participate in Upcoming Investor Conferences in May
April 30, 2024
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
April 7, 2024